Pharnext to Present at BMO 2018 Prescriptions for Success Healthcare Conference
PARIS, France, 7:30 am (CET), December 10, 2018 (CET) – Pharnext SA (FR0011191287 - ALPHA) a biopharmaceutical company pioneering a new approach to the development of innovative drug combinations based on big genomic data and artificial intelligence, today announced that company management will present a corporate overview at the BMO 2018 Prescriptions for Success Healthcare Conference in New York, NY.
The presentation will take place as follows:
- • Date: Wednesday, December 12, 2018
- • Time: 11:00 am EST (5:00 pm CEST)
If you are interested in meeting the Pharnext management team during this event, please send an email to Jane Urheim at jane@sternir.com.
About Pharnext
Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for orphan and common neurodegenerative diseases that currently lack curative and/or disease-modifying treatments. Pharnext has two products in clinical development. PXT3003 successfully completed an international pivotal Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A. PXT3003 benefits from orphan drug status in Europe and the United States. PXT864 has generated encouraging Phase 2 results in Alzheimer’s disease. Pharnext has developed a new drug discovery paradigm based on big genomic data and artificial intelligence: PLEOTHERAPY™. The Company identifies and develops synergic combinations of drugs called PLEODRUG™ offering several key advantages: efficacy, safety and robust intellectual property. The Company was founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics, and is supported by a world-class scientific team.
Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN code: FR0011191287).
For more information, visit www.pharnext.com
